New England Journal of Medicine” publishes results of MINDACT clinical trial The 70-gene test (Mammaprint®) can significantly reduce use of chemotherapy among breast cancer patients and has the potential to change clinical practice: 46% of early stage breast cancer patients classified as high-risk by traditional methods can avoid chemotherapy
The Breast International Group is proud to adhere to the Code of Ethics of the RE-EF.
Co-funded by the European Union under an operating grant from the European Union’s EU4Health programme under grant agreement No 101124555. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.